HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial

被引:133
作者
Calmy, Alexandra [1 ]
Gayet-Ageron, Angele [1 ]
Montecucco, Fabrizio [2 ]
Nguyen, Alain [1 ]
Mach, Francois [2 ]
Burger, Fabienne [2 ]
Ubolyam, Sasiwimol [3 ]
Carr, Andrew [4 ]
Ruxungtham, Kiat [3 ,5 ]
Hirschel, Bernard [1 ]
Ananworanich, Jintanat [3 ,6 ]
机构
[1] Univ Hosp Geneva, HIV Unit, CH-1205 Geneva, Switzerland
[2] Univ Hosp Geneva, Fdn Med Res, Div Cardiol, CH-1205 Geneva, Switzerland
[3] HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand
[4] St Vincents Hosp, Sydney, NSW 2010, Australia
[5] Chulalongkorn Univ, Dept Med, Fac Med, Bangkok 10330, Thailand
[6] SE Asia Res Collaborat Hawaii, Bangkok, Thailand
基金
瑞士国家科学基金会;
关键词
cardiovascular risk; HIV; HIV-RNA replication; inflammation; marker; ACTIVE ANTIRETROVIRAL THERAPY; CELL-ADHESION MOLECULE-1; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; CHEMOKINES; PROGRESSION; PREDICTION; EVENTS; DEATH; MEN;
D O I
10.1097/QAD.0b013e32832995fa
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Plasma soluble inflammatory molecules are associated with the risk of ischaemic cardiovascular events. We investigated whether HIV replication modified the levels of these proteins in a combination antiretroviral therapy (cART) interruption trial. Method and results: In 145 HIV-infected Thai patients (62% women, median CD4 cell count 271 cells/mu l, median plasma HIV-RNA 4.66 log(10) copies/ml) included in the Swiss-Thai-Australia Treatment Interruption Trial (STACCATO) trial, leptin, adiponectin, C-reactive protein, soluble vascular cell adhesion molecule-1 (s-VCAM-1), P-selectin, chemokine ligand 2, chemokine ligand 3, interleukin (IL)-6, IL-10, granulocyte macrophage colony-stimulating factor and D-dimer were measured before cART was initiated, after cART had suppressed HIV replication to less than 50 copies/ml plasma (median 8 months) and again 12 weeks after randomization to continued cART (n = 48) or interrupted cART (n = 97). Multiple linear regression and logistic regression were used to investigate the association between each cardiovascular marker and plasma HIV-RNA. Initiation of cART resulted in significant declines in s-VCAM-1, P-selectin, leptin and D-dimer, whereas mediators with anti-inflammatory properties, such as adiponectin and IL-10, increased. At 12 weeks after randomization, we found positive associations between levels of s-VCAM-1 and chemokine ligand 2 with an increase in plasma HIV-RNA (r = 0.271, P = 0.001 and r = 0.24, P = 0.005, respectively), whereas levels of adiponectin decreased for each 1 log increase in plasma HIV-RNA (r = -0.24, P = 0.002). Detectable IL-10 was less likely (odds ratio = 0.64, 95% confidence interval = 0.43-0.96) for each 1 log increase in plasma HIV-RNA. Conclusion: Plasma levels of several inflammatory, anti-inflammatory and endothelial activation markers of cardiovascular disease are associated with HIV-RNA replication. (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:929 / 939
页数:11
相关论文
共 48 条
[1]   CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1:: results of the Staccato randomised trial [J].
Ananworanich, Jintanat ;
Gayet-Ageron, Angele ;
Le Braz, Michelle ;
Prasithsirikul, Wisit ;
Chetchotisakd, Ploenchan ;
Kiertiburanakul, Sasisopin ;
Munsakul, Warangkana ;
Raksakulkarn, Phitsanu ;
Tansuphasawasdikul, Somboon ;
Sirivichayakul, Sunee ;
Cavassini, Matthias ;
Karrer, Urs ;
Genne, Daniel ;
Nueesch, Reto ;
Vernazza, Pietro ;
Bernasconi, Enos ;
Leduc, Dominic ;
Satchell, Claudette ;
Yerly, Sabine ;
Perrin, Luc ;
Hill, Andrew ;
Perneger, Thomas ;
Phanuphak, Praphan ;
Furrer, Hansjakob ;
Cooper, David ;
Ruxrungtham, Kiat ;
Hirschel, Bernard .
LANCET, 2006, 368 (9534) :459-465
[2]   AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS [J].
ANDERSON, KM ;
WILSON, PWF ;
ODELL, PM ;
KANNEL, WB .
CIRCULATION, 1991, 83 (01) :356-362
[3]   Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease [J].
Ardigo, Diego ;
Assimes, Themistocles L. ;
Fortmann, Stephen P. ;
Go, Alan S. ;
Hlatky, Mark ;
Hytopoulos, Evangelos ;
Iribarren, Carlos ;
Tsao, Philip S. ;
Tabibiazar, Raymond ;
Quertermous, Thomas .
PHYSIOLOGICAL GENOMICS, 2007, 31 (03) :402-409
[4]   Absence of favourable changes in circulating levels of interleukin-16 or β-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection [J].
Arjona, MMD ;
Cano, RP ;
Orozco, MJ ;
Aspas, AM ;
Guerrero, F ;
del Alamo, CFG ;
Girón-González, JA .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (01) :57-62
[5]   Chemokines and Cardiovascular Risk [J].
Aukrust, Pal ;
Halvorsen, Bente ;
Yndestad, Arne ;
Ueland, Thor ;
Oie, Erik ;
Otterdal, Kari ;
Gullestad, Lars ;
Damas, Jan K. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (11) :1909-1919
[6]  
Brown Pierre Antoine, 2005, J Immune Based Ther Vaccines, V3, P3, DOI 10.1186/1476-8518-3-3
[7]   The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection [J].
Coll, Blai ;
Parra, Sandra ;
Alonso-Villaverde, Carlos ;
Aragones, Gerard ;
Montero, Manuel ;
Camps, Jordi ;
Joven, Jorge ;
Masana, Lluis .
STROKE, 2007, 38 (09) :2477-2484
[8]   Function of C-reactive protein [J].
Du Clos, TW .
ANNALS OF MEDICINE, 2000, 32 (04) :274-278
[9]  
El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
[10]   Soluble P-selectin as a marker of in vivo platelet activation [J].
Ferroni, Patrizia ;
Martini, Francesca ;
Riondino, Silvia ;
La Farina, Francesca ;
Magnapera, Agesilao ;
Ciatti, Filippo ;
Guadagni, Fiorella .
CLINICA CHIMICA ACTA, 2009, 399 (1-2) :88-91